BARNES-JEWISH HOSPITAL
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
About Us
News & Events
Maps & Locations
Contact Us
Google Search
PATIENT AND VISITOR INFORMATION
TREATMENT PROGRAMS
PREVENTION AND SCREENING
RESEARCH
HOW TO HELP
FOR HEALTH PROFESSIONALS
Go back to:
Home
Treatment Programs
Types of Cancer
Clinical Trial Search Results
Share
Skin Cancer
NCI Information
Our Treatment Approach
Clinical Trials
Support Groups
Effects of Treatment
Assess Your Risk
Podcasts
Treatment Team
NEW SEARCH
RETURN TO SEARCH RESULTS
Number:
201208004
Principal Investigator:
Linette, Gerald
Title:
A phase III, randomised, open-label study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to the BRAF inhibitor vemurafenib in subjects with unresectable (stage IIIc) or metastatic (stage IV) BRAF V600E/K mutation positive cutaneous melanoma
Phase:
III
Disease Site:
Melanoma, Skin
Participating Site(s):
Main Campus
Map and Directions
Contact:
800-600-3606 or
info@ccadmin.wustl.edu
Description:
The purpose of this research study is to test the safety of dabrafenib and trametinib to see how well they work together compared to another drug, vemurafenib. The effects of the drugs, both good and bad, will be compared.
More Information:
(Links will take you off this web site)
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)